SUBSCRIBE
SUBSCRIBE
News   Policy

U.S. to Review Safety of Pfizer Inc., Procter & Gamble Cough Medicine Ingredient

May 3, 2010 | 
1 min read
Reuters -- U.S. health regulators are concerned about the potential for people to abuse a key ingredient in many cough suppressant medications, calling for a public meeting in September to weigh the issue.
Regulatory
Pfizer
MORE ON THIS TOPIC
Insights
Portugal, Spain and the new biotech frontier
June 11, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Focus on the path, Businessman running on his own track
Rare diseases
Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug
June 10, 2026
 · 
2 min read
 · 
Tristan Manalac
There is one person missing to complete the team. Recruiting workers. Workforce gaps, job recruitment, and staffing needs. Job vacancy. Talent acquisition campaigns to fill essential roles.
FDA
Busy FDA gives rare disease sector complementary pathways, unanswered questions
June 8, 2026
 · 
8 min read
 · 
Nick Paul Taylor
businessman chooses the path strategy 3d illustration
FDA
Post-Makary, new rare disease framework faces fresh uncertainty
June 8, 2026
 · 
7 min read
 · 
Heather McKenzie